CYRAMZA (ramucirumab) injection, for intravenous use. Initial U.S. Approval: 2014

INDICATIONS AND USAGE
CYRAMZA® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated:
• as a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
• in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
• in combination with docetaxel, for treatment of metastatic nonsmall cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA.
• in combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
• as a single agent, for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib.
DOSAGE FORMS & STRENGTHS
Injection: 100 mg/10 mL (10 mg/mL) or 500 mg/50 mL (10 mg/mL) solution in a single-dose vial.
Manufactured By: contact Eli Lilly and Company
Prescribing Information URL: Click Here

HOW TO MAKE AN ENQUIRY FOR CYRAMZA (ramucirumab) injection?

FDA approved Anti-Cancer medicine CYRAMZA (ramucirumab) injection is available upon request. Get best retail price of CYRAMZA (ramucirumab) injection from trusted online pharmacy. For emergency product orders call 8750295029 (Mr. Neeraj Nagpal) or For enquires email [email protected]. For advanced treatments in India, Medvitaz Pharma Solution can even help patient to discuss with Medical Oncologist.